Enovis

Enovis operated in the medical technology and industrial sectors, but struggled to achieve the growth trajectory promised during its public market debut. The company faced headwinds from supply chain disruptions, competitive pressure, and the difficult post-SPAC market environment.

The medical device market, while large, proved harder to penetrate than projected. Enovis lacked the scale of established players like Stryker and Zimmer Biomet, making it difficult to win hospital contracts and negotiate with distributors.

Operational challenges mounted as the company tried to integrate acquisitions and rationalize its portfolio. Each quarter brought disappointing results and revised guidance, eroding investor confidence.

By 2022, the stock had collapsed from its peak, and the company eventually filed for bankruptcy protection, unable to service its debt obligations in a rising interest rate environment.